MiNK Therapeutics (INKT)

• Market cap: $30.7M
• 1 day: 3.86%
• 5 days: -1.44%
• 1 month: -12.02%
• 3 months: -25.35%
• 6 months: 4.72%
• Year to date: -25.35%
• 1 year: -15.66%
• 5 years: -93.72%
• 10 years: -93.72%
• Sector: Healthcare
• Industry: Biotechnology

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Employees: 23

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0.1% less ownership

Funds ownership: 2.14% [Q3] → 2.04% (-0.1%) [Q4]

11% less capital invested

Capital invested by funds: $632K [Q3] → $565K (-$67.4K) [Q4]

12% less funds holding

Funds holding: 26 [Q3] → 23 (-3) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $35 364% upside
• Avg. target: $35 364% upside
• High target: $35 364% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 13% 1-year accuracy 20 / 160 met price target

364% upside $35

Buy Reiterated

18 Mar 2025